(Q43278789)

18 November 2017

title

High dose ara-C in the treatment of newly diagnosed acute promyelocytic leukemia: long-term results of the German AMLCG. (English)

1 reference

acute promyelocytic leukemia

18 November 2017

1 reference

1 reference

4

T Haferlach

1 reference

18 November 2017

2

C Haferlach

1 reference

18 November 2017

6

S Schnittger

1 reference

18 November 2017

E Lengfelder

1

1 reference

18 November 2017

S Saussele

3

1 reference

18 November 2017

B Schultheis

5

1 reference

18 November 2017

W-D Ludwig

7

1 reference

18 November 2017

P Staib

8

1 reference

18 November 2017

C Aul

9

1 reference

18 November 2017

A Grüneisen

10

1 reference

18 November 2017

W Kern

11

1 reference

18 November 2017

A Reichle

12

1 reference

18 November 2017

H Serve

13

1 reference

18 November 2017

W E Berdel

14

1 reference

18 November 2017

J Braess

15

1 reference

18 November 2017

K Spiekermann

16

1 reference

18 November 2017

B Wörmann

17

1 reference

18 November 2017

M-C Sauerland

18

1 reference

18 November 2017

A Heinecke

19

1 reference

18 November 2017

W Hiddemann

20

1 reference

18 November 2017

R Hehlmann

21

1 reference

18 November 2017

T Büchner

22

1 reference

18 November 2017

German AML Cooperative Group

23

1 reference

18 November 2017

language of work or name

1 reference

10 September 2009

1 reference

18 November 2017

1 reference

18 November 2017

volume

23

1 reference

18 November 2017

issue

12

1 reference

18 November 2017

page(s)

2248-2258

1 reference

https://scigraph.springernature.com/pub.10.1038/leu.2009.183

18 November 2017

exact match

0 references

cites work

Risk-adapted treatment of acute promyelocytic leukemia with all-trans retinoic acid and anthracycline monochemotherapy: long-term outcome of the LPA 99 multicenter study by the PETHEMA Group.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.183

Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.183

All-trans retinoic acid in acute promyelocytic leukemia: long-term outcome and prognostic factor analysis from the North American Intergroup protocol.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.183

A randomized study with or without intensified maintenance chemotherapy in patients with acute promyelocytic leukemia who have become negative for PML-RARalpha transcript after consolidation therapy: the Japan Adult Leukemia Study Group (JALSG) APL9

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.183

Gemtuzumab ozogamicin (Mylotarg) as a single agent for molecularly relapsed acute promyelocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.183

Treatment of newly diagnosed acute promyelocytic leukemia (APL): a comparison of French-Belgian-Swiss and PETHEMA results

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.183

All-trans retinoic acid for acute promyelocytic leukemia. Results of the New York Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.183

Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.183

Nonparametric Estimation from Incomplete Observations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.183

Cytosine arabinoside in the treatment of acute myeloid leukemia: the role and place of high-dose regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.183

Myelodysplastic syndrome after acute promyelocytic leukemia: the European APL group experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.183

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.183

Causes and prognostic factors of remission induction failure in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and idarubicin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.183

Early haemorrhagic morbidity and mortality during remission induction with or without all-trans retinoic acid in acute promyelocytic leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.183

Differentiation syndrome in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline chemotherapy: characteristics, outcome, and prognostic factors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.183

Is Cytarabine Useful in the Treatment of Acute Promyelocytic Leukemia? Results of a Randomized Trial From the European Acute Promyelocytic Leukemia Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.183

Treatment of newly diagnosed acute promyelocytic leukemia without cytarabine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.183

7 January 2021

Double induction strategy including high dose cytarabine in combination with all-trans retinoic acid: effects in patients with newly diagnosed acute promyelocytic leukemia. German AML Cooperative Group

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.183

7 January 2021

Estimation of failure probabilities in the presence of competing risks: new representations of old estimators

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.183

7 January 2021

Antileukemic activity of 4-demethoxydaunorubicin in mice

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.183

7 January 2021

Severe hemorrhagic complications during remission induction therapy for acute promyelocytic leukemia: incidence, risk factors, and influence on outcome

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.183

7 January 2021

Identifiers

DOI

10.1038/LEU.2009.183

1 reference

Dimensions Publication ID

18 November 2017

1040915796

0 references

1 reference